Benitec Biopharma Inc.

12.25
-0.76 (-5.84%)
At close: Apr 04, 2025, 2:39 PM

Company Description

Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines.

The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions.

It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection.

The company was incorporated in 1995 and is headquartered in Hayward, California.

Benitec Biopharma Inc.
Benitec Biopharma Inc. logo
Country United States
IPO Date Jun 24, 2014
Industry Biotechnology
Sector Healthcare
Employees 16
CEO Dr. Jerel A. Banks M.D., Ph.D.

Contact Details

Address:
3940 Trust Way
Hayward, California
United States
Website https://benitec.com

Stock Details

Ticker Symbol BNTC
Exchange NASDAQ
Fiscal Year July - June
Reporting Currency USD
CIK Code 0001808898
CUSIP Number 08205P100
ISIN Number US08205P2092
Employer ID 00-0000000
SIC Code 2834

Key Executives

Name Position
Dr. Jerel A. Banks M.D., Ph.D. Executive Chairman & Chief Executive Officer
Megan Joan Boston B.Com., C.A. Chief Financial Officer & Director
Sophie Mukadam Chief Operating Officer
Dr. Claudia Kloth Ph.D. Senior Vice President of Manufacturing
Dr. Michael Graham Head of Discovery & Founding Scientist

Latest SEC Filings

Date Type Title
Apr 02, 2025 4 Filing
Mar 28, 2025 8-K Current Report
Mar 28, 2025 4 Filing
Mar 28, 2025 SCHEDULE 13D/A [Amend] Filing
Mar 27, 2025 8-K Current Report
Mar 26, 2025 424B5 Filing
Mar 26, 2025 8-K Current Report
Mar 20, 2025 8-K Current Report
Mar 19, 2025 8-K Current Report
Mar 13, 2025 4 Filing